Viatris Trims FY22 Revenue Outlook, Declares Dividend - Update

While reporting financial results for the second quarter on Monday, healthcare company Viatris Inc. (VTRS) trimmed its total revenue guidance for the full-year 2022 to reflect the incremental impact of foreign exchange.

For fiscal 2022, the company no projects total revenue between $16.2 billion and $15.7 billion, down from the prior forecast range of $17.0 billion to $17.5 billion. On average, ten analysts polled by Thomson Reuters expect the company to report revenues of $17.04 billion for the year.

The company also said its Board of Directors declared a 9 percent higher quarterly dividend of $0.12 for each issued and outstanding share of the company's common stock, payable on September 16, 2022, to shareholders of record at the close of business on August 24, 2022.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Activity in the U.S. manufacturing sector slowed by more than expected in the month of September but still saw continued growth, according to a report released by the Institute for Supply Management on Monday. Stocks have moved sharply higher in morning trading on Monday, regaining ground following a dismal September. The major averages have all shown substantial moves to the upside. Swedish geneticist Svante Paabo has won this year's Nobel Prize in Physiology/Medicine for his discoveries concerning the genomes of extinct hominins and human evolution. Through his pioneering research, Svante Pääbo accomplished something seemingly impossible: sequencing the genome of the Neanderthal, an extinct relative of present-day humans. He also made the sensational discovery of a previous
Follow RTT